Engelhard, Matthew M.
Berchuck, Samuel I.
Garg, Jyotsna
Henao, Ricardo
Olson, Andrew
Rusincovitch, Shelley
Dawson, Geraldine
Kollins, Scott H.
Funding for this research was provided by:
National Institute of Mental Health (R01MH121329)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD093074)
National Institute on Drug Abuse (K24DA023464)
Article History
Received: 6 April 2020
Accepted: 28 September 2020
First Online: 19 October 2020
Competing interests
: Geraldine Dawson is on the Scientific Advisory Boards of Janssen Research and Development, Akili, Inc., LabCorp, Inc., Tris Pharma, and Roche Pharmaceutical Company, a consultant for Apple, Inc, Gerson Lehrman Group, Guidepoint, Inc., Teva Pharmaceuticals, and Axial Ventures, and is CEO of DASIO, LLC. Dawson has developed technology that has been licensed and Dawson and Duke University have benefited financially. Dawson receives royalties from Guilford Press, Springer, and Oxford University Press. Scott Kollins reports grants, personal fees and non-financial support from Akili Interactive; grants, personal fees and non-financial support from Arbor Pharmaceuticals; grants, personal fees and non-financial support from Bose; grants, personal fees and non-financial support from Otsuka Pharmaceuticals; grants, personal fees and non-financial support from Rhodes; grants, personal fees and non-financial support from Shire Pharmaceuticals; and grants, personal fees and non-financial support from Tris Pharmaceuticals outside the submitted work. Matthew Engelhard, Samuel Berchuck, Jyotsna Garg, Ricardo Henao, Andrew Olson, and Shelley Rusincovitch have no financial relationships or potential conflicts of interest relevant to this article.